A 30-year-old traveller develops P. vivax malaria in India. He is treated with chloroquine and primaquine. He is known to be a CYP2D6 poor metaboliser...

Question

A 30-year-old traveller develops P. vivax malaria in India. He is treated with chloroquine and primaquine. He is known to be a CYP2D6 poor metaboliser. What is the clinical implication?

Accepted Answer

CYP2D6 poor metabolisers may fail to adequately metabolise primaquine to its active metabolites, potentially reducing efficacy of radical cure and increasing relapse risk

Answer

No effect on treatment efficacy

Answer

CYP2D6 status only affects quinine metabolism

Answer

Poor metabolisers have enhanced primaquine efficacy

Answer

CYP2D6 status affects chloroquine but not primaquine

uk-dtmh MCQ (SBA): CYP2D6 and Primaquine Efficacy

A 30-year-old traveller develops P. vivax malaria in India. He is treated with chloroquine and primaquine. He is known to be a CYP2D6 poor metaboliser. What is the clinical implication?